Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Emerging Roles for the INK4a/ARF ( CDKN2A ) Locus in Adipose Tissue: Implications for Obesity and Type 2 Diabetes

Kahoul Y., Oger F., Montaigne J., Froguel P., Breton C., Annicotte JS.

Narrative Review on Type 2 Diabetes, published in Biomolecules (2020) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Biomolecules (2020)
Reported sample size
—
Source database
Europe PMC
PMID
32971832
PMCID
PMC7563355
DOI
10.3390/biom10091350
Citations
21

Abstract (original English)

Besides its role as a cell cycle and proliferation regulator, the INK4a/ARF ( CDKN2A ) locus and its associated pathways are thought to play additional functions in the control of energy homeostasis. Genome-wide association studies in humans and rodents have revealed that single nucleotide polymorphisms in this locus are risk factors for obesity and related metabolic diseases including cardiovascular complications and type-2 diabetes (T2D). Recent studies showed that both p16 INK4a -CDK4-E2F1/pRB and p19 ARF -P53 (p14 ARF in humans) related pathways regulate adipose tissue (AT) physiology and adipocyte functions such as lipid storage, inflammation, oxidative activity, and cellular plasticity (browning). Targeting these metabolic pathways in AT emerged as a new putative therapy to alleviate the effects of obesity and prevent T2D. This review aims to provide an overview of the literature linking the INK4a/ARF locus with AT functions, focusing on its mechanisms of action in the regulation of energy homeostasis.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsHumansDiabetes Mellitus, Type 2Insulin ResistanceObesityDNA MethylationGene Expression RegulationPolymorphism, Single NucleotideCyclin-Dependent Kinase Inhibitor p16

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research